Does TILDRAKIZUMAB Cause Inappropriate schedule of product administration? 22 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Inappropriate schedule of product administration have been filed in association with TILDRAKIZUMAB (ILUMYA). This represents 2.5% of all adverse event reports for TILDRAKIZUMAB.
22
Reports of Inappropriate schedule of product administration with TILDRAKIZUMAB
2.5%
of all TILDRAKIZUMAB reports
3
Deaths
6
Hospitalizations
How Dangerous Is Inappropriate schedule of product administration From TILDRAKIZUMAB?
Of the 22 reports, 3 (13.6%) resulted in death, 6 (27.3%) required hospitalization.
Is Inappropriate schedule of product administration Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TILDRAKIZUMAB. However, 22 reports have been filed with the FAERS database.
What Other Side Effects Does TILDRAKIZUMAB Cause?
Product dose omission issue (53)
Death (50)
Drug ineffective (50)
Psoriasis (37)
Urinary tract infection (36)
Pneumonia (33)
Off label use (27)
Condition aggravated (25)
Covid-19 (25)
Cerebrovascular accident (20)
What Other Drugs Cause Inappropriate schedule of product administration?
ADAPALENE (16,473)
DUPILUMAB (14,927)
AVOBENZONE\OCTISALATE\OCTOCRYLENE (12,546)
INSULIN GLARGINE (8,982)
INFLIXIMAB (6,847)
INFLIXIMAB-DYYB (5,977)
SECUKINUMAB (4,817)
DULAGLUTIDE (3,606)
VEDOLIZUMAB (3,259)
SACUBITRIL\VALSARTAN (2,870)
Which TILDRAKIZUMAB Alternatives Have Lower Inappropriate schedule of product administration Risk?
TILDRAKIZUMAB vs TILDRAKIZUMAB-ASMN
TILDRAKIZUMAB vs TILIDINE
TILDRAKIZUMAB vs TIMOLOL
TILDRAKIZUMAB vs TIMOLOL\TRAVOPROST
TILDRAKIZUMAB vs TINIDAZOLE